Brolucizumab extends treatment intervals with comparable vision outcomes in nAMD study
A Phase 3b study has shown that brolucizumab 6 mg may allow for longer treatment intervals compared to aflibercept 2 mg in patients with neovascular age-related macular degeneration (nAMD), without compromising visual outcomes.
The TALON trial, which included 737 treatment-naïve patients, used an identical Treat-and-Extend protocol with 4-week interval adjustments based on disease activity. At Week 32, 38.5% of patients on brolucizumab maintained 12-week dosing intervals versus 19.8% on aflibercept (P < 0.0001). Visual acuity gains were similar between the groups at Weeks 28 and 32, confirming brolucizumab’s non-inferiority (+5.2 vs +5.1 letters).
Brolucizumab also led to greater reductions in central subfield thickness and fewer patients with persistent retinal fluid. However, rates of serious ocular adverse events were higher in the brolucizumab group (2.5% vs 0.5%).
Reference
Regillo C, Kaiser PK, Kertes PJ, et al. TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration. Ophthalmol Retina. 2025;S2468-6530(25)00267-2. doi: 10.1016/j.oret.2025.05.030. Epub ahead of print. PMID: 40466770.
Related Content
